Genvor Inc. Reports Material Agreement, Officer Comp Changes

TL;DR

**Genvor Inc. just signed a big deal and changed exec pay, watch for details.**

AI Summary

Genvor Inc. filed an 8-K on January 23, 2024, reporting a material definitive agreement and changes in officer compensatory arrangements, effective January 17, 2024. This filing indicates potential strategic shifts or new business ventures for Genvor, which could impact its financial performance and future growth prospects. Investors should monitor subsequent filings for details on the agreement and its implications for the company's valuation and operational strategy.

Why It Matters

This filing signals Genvor Inc. is entering into significant new commitments and potentially adjusting executive incentives, which could influence the company's direction and financial health. Investors need to understand the nature of these agreements to assess future revenue streams or liabilities.

Risk Assessment

Risk Level: medium — The filing mentions a 'material definitive agreement' without disclosing its specifics, creating uncertainty about its potential impact on the company's financial position and future operations.

Analyst Insight

A smart investor would await further details on the 'Material Definitive Agreement' and the 'Compensatory Arrangements of Certain Officers' to understand their financial implications before making investment decisions. This filing is a signal, not a complete picture.

Key Players & Entities

• Genvor Inc. (company) — the registrant filing the 8-K
• January 17, 2024 (date) — date of the earliest event reported
• January 23, 2024 (date) — date the 8-K was filed
• Nevada (company) — state of incorporation for Genvor Inc.
• 000-56589 (company) — Commission File Number for Genvor Inc.

Forward-Looking Statements

• Genvor Inc. will release further details about the 'Material Definitive Agreement' in a subsequent filing. (Genvor Inc.) — high confidence, target: Q1 2024
• The 'Compensatory Arrangements of Certain Officers' will involve changes to executive stock options or bonuses. (Genvor Inc.) — medium confidence, target: Q1 2024

FAQ

Key Financial Figures

• $30 million — n of the strategic business plan of the $30 million Botanical & Organic Crop Protection seg
• $300,000 — r. Pawlak will receive a base salary of $300,000 per year; (ii) Mr. Pawlak will be eligi
• $10,000,000 — pon the commercial sale of a minimum of $10,000,000 of the topical spray; and (vii) Mr. Paw
• $180,000 — s. Miller will receive a base salary of $180,000 per year; (ii) Ms. Miller will be issue
• $1,000,000 — k upon the Company raising each tranche $1,000,000 up to an aggregate of $10,000,000; (v)
• $2,500,000 — y common stock upon the Company raising $2,500,000; (vi) Ms. Miller will receive an additi
• $6,000,000 — y common stock upon the Company raising $6,000,000, and (vii) Ms. Miller will receive an a
• $50,000 — follows: (i) Dr. Jaynes will be paid a $50,000 signing bonus; (ii) Dr. Jaynes will be
• $5,000 — ing bonus; (ii) Dr. Jaynes will be paid $5,000 per month; (iii) Dr. Jaynes will be pai
• $100,000 — er month; (iii) Dr. Jaynes will be paid $100,000 and 25,000 shares of Company common sto

Filing Documents

• form8-k.htm (8-K) — 60KB
• ex10-1.htm (EX-10.1) — 177KB
• ex10-2.htm (EX-10.2) — 188KB
• ex10-3.htm (EX-10.3) — 81KB
• ex10-3_001.jpg (GRAPHIC) — 9KB
• ex10-4.htm (EX-10.4) — 82KB
• ex10-4_001.jpg (GRAPHIC) — 3KB
• ex10-5.htm (EX-10.5) — 66KB
• ex10-6.htm (EX-10.6) — 66KB
• ex10-7.htm (EX-10.7) — 66KB
• ex10-8.htm (EX-10.8) — 73KB
• 0001493152-24-003418.txt ( ) — 1217KB
• gen-20240117.xsd (EX-101.SCH) — 3KB
• gen-20240117_lab.xml (EX-101.LAB) — 34KB
• gen-20240117_pre.xml (EX-101.PRE) — 22KB
• form8-k_htm.xml (XML) — 3KB

Financial Statements and Exhibits

Financial Statements and Exhibits. The exhibits listed in the following Exhibit Index are filed as part of this report: Exhibit No. Description 10.1 Employment Agreement, by and between Genvor Incorporated and Chad Pawlak, dated January 17, 2024 10.2 Employment Agreement, by and between Genvor Incorporated and Judith S. Miller, dated January 17, 2024 10.3 Science Advisor Agreement, by and between Genvor Incorporated and Jesse Jaynes, dated January 16, 2024 10.4 Science Advisor Agreement, by and between Genvor Incorporated and Clayton Yates, dated January 16, 2024 10.5 Indemnification Agreement, by and between Genvor Incorporated and Chad Pawlak, dated January 17, 2024 10.6 Indemnification Agreement, by and between Genvor Incorporated and Judith S. Miller, dated January 17, 2024 10.7 Indemnification Agreement, by and between Genvor Incorporated and Jesse Jaynes, dated January 17, 2024 10.8 Indemnification Agreement, by and between Genvor Incorporated and Clayton Yates, dated January 17, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. GENVOR INCORPORATED Dated: January 23, 2024 By: /s/ Chad Pawlak Chad Pawlak Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR